Liraglutide reduces CNS activation in response to visual food cues only after short-term treatment in patients with type 2 diabetes

Diabetes Care

Volumn 39, Issue 2, 2016, Pages 214-221

  Ten Kulve, Jennifer S ^a   Veltman, Dick J ^a   Van Bloemendaal, Liselotte ^a   Barkhof, Frederik ^a   Drent, Madeleine L ^a   Diamant, Michaela ^a   IJzerman, Richard G ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE; HEMOGLOBIN A1C; INSULIN GLARGINE; LIRAGLUTIDE; METFORMIN; SULFONYLUREA DERIVATIVE; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1; GLUCOSE BLOOD LEVEL; INSULIN;

ADULT; AGED; ARTICLE; CENTRAL NERVOUS SYSTEM; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DECREASED APPETITE; DIARRHEA; DIET RESTRICTION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG RESPONSE; EVENING DOSAGE; FEMALE; FOOD; FOOD INTAKE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULA; LONG TERM CARE; MALE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PUTAMEN; RANDOMIZED CONTROLLED TRIAL; SATIETY; SHORT COURSE THERAPY; VISUAL STIMULATION; VOMITING; WEIGHT REDUCTION; ASSOCIATION; BODY WEIGHT; BRAIN; COMPLICATION; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY;

BLOOD GLUCOSE; BODY WEIGHT; BRAIN; CROSS-OVER STUDIES; CUES; DIABETES MELLITUS, TYPE 2; FASTING; FEMALE; FOOD; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN GLARGINE; LIRAGLUTIDE; MALE; MIDDLE AGED; OBESITY; SATIATION;

EID: 84962130451     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc15-0772     Document Type: Article

References (40)

1. Whiting DR, Guariguata L, Weil C, Shaw J. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 2011;94:311-321
2. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and mi-crovascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-412
3. Volkow ND, Wang GJ, Tomasi D, Baler RD. Obesity and addiction: neurobiological overlaps. Obes Rev 2013;14:2-18
4. Rothemund Y, Preuschhof C, Bohner G, et al. Differential activation of the dorsal striatum by high-calorie visual food stimuli in obese individuals. Neuroimage 2007;37:410-421
5. Stoeckel LE, Weller RE, Cook EW 3rd, Twieg DB, Knowlton RC, Cox JE. Widespread reward-system activation in obese women in response to pictures of high-calorie foods. Neuroimage 2008;41:636-647
6. Schwartz MW, Woods SC, Porte D Jr, Seeley RJ, Baskin DG. Central nervous system control of food intake. Nature 2000;404:661-671
7. Costantini VJ, Vicentini E, Sabbatini FM, et al. GSK1614343, a novel ghrelin receptor antagonist, produces an unexpected increase of food intake and body weight in rodents and dogs. Neuroendocrinology 2011;94:158-168
8. Cummings BP. Leptin therapy in type 2 diabetes. Diabetes Obes Metab 2013;15:607-612
9. Eissele R, Göke R, Willemer S, et al. Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man. Eur J Clin Invest 1992;22:283-291
10. Kreymann B, Williams G, Ghatei MA, Bloom SR. Glucagon-like peptide-17-36:aphysiological incretin in man. Lancet 1987;2:1300-1304
11. Vilsbøll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ 2012;344:d7771
12. Turton MD, O'Shea D, Gunn I, et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 1996;379:69-72
13. Williams DL, Baskin DG, Schwartz MW. Evidence that intestinal glucagon-like peptide-1 plays a physiological role in satiety. Endocrinology 2009;150:1680-1687
14. van Bloemendaal L, IJzerman RG, ten Kulve JS, et al. GLP-1 receptor activation modulates appetite-and reward-related brain areas in humans. Diabetes 2014;63:4186-4196
15. Tang DW, Fellows LK, Small DM, Dagher A. Food and drug cues activate similar brain regions: a meta-analysis of functional MRI studies. Physiol Behav 2012;106:317-324
16. Yki-Järvinen H, Juurinen L, Alvarsson M, et al. Initiate Insulin by Aggressive Titration and Education (INITIATE): a randomized study to compare initiation of insulin combination therapy in type 2 diabetic patients individually and in groups. Diabetes Care 2007;30:1364-1369
17. Verdich C, Flint A, Gutzwiller JP, et al. A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans. J Clin Endocrinol Metab 2001;86:4382-4389
18. Buse JB, Rosenstock J, Sesti G, et al.; LEAD-6 Study Group. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009;374:39-47
19. Pursey KM, Stanwell P, Callister RJ, Brain K, Collins CE, Burrows TL. Neural responses to visual food cues according to weight status: a systematic review of functional magnetic resonance imaging studies. Front Nutr 2014;1:7
20. Bruce JM, Hancock L, Bruce A, et al. Changes in brain activation to food pictures after adjustable gastric banding. Surg Obes Relat Dis 2012;8:602-608
21. Yokum S, Ng J, Stice E. Attentional bias to food images associated with elevated weight and future weight gain: an fMRI study. Obesity (Silver Spring) 2011;19:1775-1783
22. Murdaugh DL, Cox JE, Cook EW 3rd, Weller RE. fMRI reactivity to high-calorie food pictures predicts short-and long-term outcome in a weight-loss program. Neuroimage 2012;59:2709-2721
23. Levy LM, Henkin RI, Lin CS, Finley A, Schellinger D. Taste memory induces brain activation as revealed by functional MRI. J Comput Assist Tomogr 1999;23:499-505
24. Frank S, Kullmann S, Veit R. Food related processes in the insular cortex. Front Hum Neu-rosci 2013;7:499
25. Baxter MG, Murray EA. The amygdala and reward. Nat Rev Neurosci 2002;3:563-573
26. Arana FS, Parkinson JA, Hinton E, Holland AJ, Owen AM, Roberts AC. Dissociable contributions of the human amygdala and orbitofrontal cortex to incentive motivation and goal selection. J Neurosci 2003;23:9632-9638
27. O'Doherty J, Dayan P, Schultz J, Deichmann R, Friston K, Dolan RJ. Dissociable roles of ventral and dorsal striatum in instrumental conditioning. Science 2004;304:452-454
28. Gao Q, Horvath TL. Neuronal control of energy homeostasis. FEBS Lett 2008;582:132-141
29. Secher A, Jelsing J, Baquero AF, et al. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. J Clin Invest 2014;124:4473-4488
30. Hunter K, Hölscher C. Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogen-esis. BMC Neurosci 2012;13:33
31. Plamboeck A, Veedfald S, Deacon CF, et al. The effect of exogenous GLP-1 on food intake is lost in male truncally vagotomized subjects with pyloroplasty. Am J Physiol Gastrointest Liver Physiol 2013;304:G1117-G1127
32. Horowitz M, Vilsbøll T, Zdravkovic M, Hammer M, Madsbad S. Patient-reported rating of gastrointestinal adverse effects during treatment of type 2 diabetes with the once-daily human GLP-1 analogue, liraglutide. Diabetes Obes Metab 2008;10:593-596
33. Schirra J, Wank U, Arnold R, Göke B, Katschinski M. Effects of glucagon-like peptide-1 (7-36)amide on motility and sensation of the proximal stomach in humans. Gut 2002;50:341-348
34. Jelsing J, Vrang N, Hansen G, Raun K, Tang-Christensen M, Knudsen LB. Liraglutide: shortlived effect on gastric emptying-long lasting effects on body weight. Diabetes Obes Metab 2012;14:531-538
35. van Can J, Sloth B, Jensen CB, Flint A, Blaak EE, Saris WH. Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults. Int J Obes (Lond) 2014;38:784-793
36. Nauck M, Frid A, Hermansen K, et al.; LEAD-2 Study Group. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 2009;32:84-90
37. Gutzwiller JP, Drewe J, Göke B, et al. Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol 1999;276:R1541-R1544
38. Page KA, Seo D, Belfort-DeAguiar R, et al. Circulating glucose levels modulate neural control of desire for high-calorie foods in humans. J Clin Invest 2011;121:4161-4169
39. Garber A, Henry RR, Ratner R, Hale P, Chang CT, Bode B; LEAD-3 (Mono) Study Group. Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes. Diabetes Obes Metab 2011;13:348-356
40. Inokuchi A, Oomura Y, Nishimura H. Effect of intracerebroventricularly infused glucagon on feeding behavior. Physiol Behav 1984;33: 397-400